EyePoint Pharmaceuticals, formerly pSivida, reported a net loss of $7 million, or $0.15 per share, in its third fiscal quarter compared with a net loss of $5.1 million, or $0.15 per share, in the same quarter of 2017.
Revenue for the quarter was $928,000 compared with $590,000 a year ago, according to a press release.
Quarterly operating expenses decreased from $5.8 million in 2017 to $5.6 million in 2018.
The company had cash and cash equivalents of $16.3 million as of March 31.
Uncategorized